Optinose US

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Optinose US sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 9 completed later-stage tilt top decile by trial count

Optinose US: 11 sponsored US clinical trials, 2 recruiting.

Optinose US sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 9 completed. 10 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bilateral Nasal Polyposis, with 2 trials.

Top-decile sponsor footprint

Optinose US ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

NCT06850805
RECRUITING Phase 3

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

NCT03747458
COMPLETED Phase 3

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

NCT03960580
COMPLETED Phase 3

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

NCT03781804
COMPLETED Phase 3

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

NCT03591068
COMPLETED Phase 3

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

NCT01622569
COMPLETED Phase 3

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

NCT01624662
COMPLETED Phase 3

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

NCT01623323
COMPLETED Phase 3

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

NCT01623310
COMPLETED Phase 1

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

NCT01507610
COMPLETED Phase 3

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

NCT01462812

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 10

Therapeutic Areas

Bilateral Nasal Polyposis 2
Nasal Polyposis 1
Chronic Rhinosinusitis 1
Chronic Rhinosinusitis Without Nasal Polyps 1

Where Optinose US enrollment is open (later-stage tilt)

2 recruiting of 11 indexed (18% open); 9 completed (82%).

Phase mix: 10 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Bilateral Nasal Polyposis (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Optinose US: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Optinose US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10.910.91111.1 0%5%10%15%20% Total trials Recruiting share Optinose USAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityImunonInventisBio Co.
Optinose US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Optinose US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Optinose US page

11 registered trials is a research-attention snapshot, not an endorsement of Optinose US or any single study.

  • 2 of Optinose US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Bilateral Nasal Polyposis is the condition Optinose US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bilateral Nasal Polyposis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Optinose US pipeline card: 11 registered trials from official public datasets.Report a data error.